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Outcomes of screening to prevent cancer
Think of screening as insurance
Editor—Raffle et al provide interesting new
data on the outcome of cervical screening.1 It
is particularly useful to be able to tell women
that over 20 years of five yearly screening,
around 16% will have an abnormal smear test
result, 8% will have a biopsy, and 4% will be
treated for high grade disease.
The authors also estimate the number of
cancers and deaths that might be prevented
over 30 years in such a cohort. How they
obtained their estimates is unclear, but num-
bers are surprisingly low. When estimating
the number of premature deaths avoided in
screened women, they apply the factor 60%,
obtained from a population in which
approximately one in five eligible women
are not screened regularly. In screened
women the figure should be closer to 75%,
which is more in keeping with the results
from case-control studies.2 3
Fitting an age cohort model to mortality
data from England and Wales for 1950-87
and extrapolating to 2011, we estimate the
cumulative number of deaths in an
unscreened cohort to be some 50% greater
than do Raffle et al. Assuming that 75% of
the deaths after 1996 would be prevented in
a screened cohort, the number of premature
deaths avoided is 2.4 times greater than in
the paper. Over the next 30 years, the effect
of screening in women born in the early
1960s will be much greater—some 2% of
those screened will be prevented from
developing cervical cancer.
Describing the benefits of screening in
terms of the number needed to be screened
to prevent one death equates screening with
treatment. Screening is not treatment. It is
perhaps better to think of it as insurance. The
issue is not how many need to be insured for
one person to avoid bankruptcy. It is not even
simply a question of whether the cost of an
insurance premium is more or less than the
expected pay out (it will always be more).
Insurance is put in place to avoid
catastrophic consequences of an unlikely
event. Women need to be aware of the com-
mon negative consequences of regular
screening, but they should perhaps think of
it as a costly and imperfect insurance policy
that may save them from the horrors of
invasive cervical cancer.
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Authors’ reply
Editor—We agree that screening can be
thought of like insurance. It is not the likeli-
hood of a house fire that makes you pay
your premiums, it is the seriousness.
We believe numbers screened are valu-
able. Policy about screening is unsatisfactory
in that support for, or dismissal of, the worth
of screening programmes is dominated by
advocacy rather than scientific debate.1 Part
of the reason this situation persists is that the
literature is so hard to understand. It is full of
statistical jargon, opaque terminology, and
flawed concepts. We need to present
complete information about all conse-
quences of screening in an easily under-
standable way. People understand numbers
and explanations in plain English, far better
than probabilities, percentages, or sensitivity
and specificity.2
Sasieni questions our estimates of cases
and deaths. Our adjustment for “without
screening” is as shown in figures 6.6 and 6.8
of page 51 of the reference we gave.3 We are
happy to share our calculations, and without
access to the age breakdown of our cohort
we are unsure how alternative estimates can
be derived.
We tested varying assumptions for mor-
tality reduction after 1996. Even if 75% of
deaths in our study population are pre-
vented after 1996, our conclusion is still that
screening is very labour intensive, with 790
women screened for 35 years to prevent one
death, involving 6098 tests. We view case-
control studies with caution.4
We can all hope that future benefits will
be substantial, but we cannot let this divert
us from the sobering finding that before
1996 there were 57 000 tests and 1955
women with abnormal results for each death
prevented. Misguided media campaigns are
already causing a repetition of this situation
with prostate cancer screening. Invasive
investigations and treatments for 2000, in
the hope of possibly helping one, will
seriously damage men’s health.
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Effectiveness of lipid lowering
drugs in general practice
Article illustrates major problem
Editor—The article by Hippisley-Cox et al
illustrates a major problem of describing a
recommended cholesterol concentration as
a target value—scatter around a bullseye will
always ensure at least 50% of values above
the target.1 What was most interesting about
their data was the dispersion of last recorded
serum cholesterol concentrations about the
means. This was small for simvastatin and
atorvastatin, indicating that cholesterol
values were close to recommended values
even for those > 5 mmol/l, and as Marshall
has implied,2 many of these patients
may have concentrations <5 mmol/l on
remeasurement.
Although only one trial has compared
five statins in a single study,3 several paired
comparisons of the efficacy of the statins4
and of statins versus fibrates5 have been
undertaken. The data of Hippisley-Cox et al
are consistent with these.
However, the statement “Statins reduce
lipid levels better than fibrates” is at best
misleading. Fibrates are often used in
diabetic patients and other patients with an
atherogenic lipoprotein phenotype (raised
triglyceride, low high density lipoprotein,
and mildly raised low density lipoprotein
cholesterol concentrations), in whom chol-
Letters
50 BMJ VOLUME 327 5 JULY 2003 bmj.com
esterol lowering is not the only considera-
tion. Fibrates are also often used in
combination treatment or in patients intol-
erant or poorly responsive to statins. Hence
Marshall may be wrong to dismiss selection
bias as a confounding problem. It was
unclear whether patients receiving com-
bined treatment were excluded from the
analysis, and if included, which starting chol-
esterol concentrations were chosen. The lack
of dosing data also makes it difficult to assess
the validity of the statement that a target
value of <5 mmol/l is unrealistic.
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Study had two major flaws
Editor—The paper by Hippisley-Cox et al
is a large study of how prescribed drugs are
used in the community and gives a useful
picture of the lipid lowering drugs used and
their effectiveness.1 It has two major flaws,
however.
The first is the omission to report the
characteristics of patients receiving different
drugs. The pretreatment cholesterol con-
centrations in patients prescribed different
statins differed, implying non-random selec-
tion of drug. In non-randomised studies dif-
ferences among treatment groups may be
systematic, substantial, and consequential.
Extreme differences might require matching
of subpopulations for comparisons.
The second problem is the omission of
drug dosage in the analysis, although the
data were collected. The authors probably
assumed that the clinician could adjust the
dose to achieve target and therefore failure
to reach target implied lack of efficacy.
Although statins have pertinent differences
in potency and efficacy,2 “recommended
dosage” could be another confounding
factor. In the British National Formulary, the
highest recommended daily dose for prava-
statin is only 40 mg whereas atorvastatin is
licensed for use at 80 mg. The lipid lowering
efficacy of 40 mg of the former is equivalent
to only 10 mg of the latter.2
Under these circumstances, failure to
reveal and discuss the dosages of the
various drugs in the study seriously under-
mines the conclusions drawn. A blanket
endorsement of atorvastatin and simva-
statin as the more effective statins over-
simplifies an important subject and might
inadvertently provide a pseudoscientific
basis for misleading advertisements.
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Authors’ reply
Editor—Wang et al, and Kumana and
Cheung are concerned by the omission of
data on drug dosage. We included an analy-
sis of drug dosage in the original paper sub-
mitted to the BMJ and removed it at the
request of the editorial board. Of the 1116
patients whose serum cholesterol value was
above 5 mmol/l, 209 (18.7%) were receiving
maximum doses compared with 96 (7.1%)
of the 1353 patients who did achieve the
target range. In addition, in those patients
receiving the maximum dose only 32% (96)
achieved the target cholesterol value.
The table shows the number of patients
taking each drug who reached target choles-
terol values according to whether the maxi-
mum dose recommended in the British
National Formulary had been prescribed.
However, we have not looked at equivalent
doses when these are submaximal for one
drug, but maximal for another.
We did not write the statement “Statins
reduce lipid levels better than fibrates”—this
appeared in This week in the BMJ rather
than in our paper. The text was different
from the version we submitted, and we had
no opportunity to comment on it before
publication.
Kumana and Cheung raise the issue of
differences between patients taking different
statins. As we described in our paper, we
took account of potential confounders by
including the following variables in the
multivariate analysis: sex, age, obesity,
smoking status, pretreatment cholesterol
values, comorbidity (ischaemic heart disease,
diabetes, hypertension, and stroke), and reg-
istered general practices. We discussed the
potential effect on the results in our
discussion.
We think that the “dispersion” men-
tioned by Wang et al refers to the 95% confi-
dence intervals (which are not standard
deviations), and naturally these are narrower
for atorvastain and simvastatin because of
the larger sample sizes in those groups.
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Assisted suicide and
euthanasia in Switzerland
Doctors occupy special position
Editor—I agree with Hurst and Mauron
that the Swiss penal code illustrates how
important it is to separate the issue of
whether assisting death should be allowed in
some circumstances from that of whether
doctors should do it.1 Assistance in dying
raises questions that cannot be answered
from the perspective of medicine alone.
We should not, however, be misled into
denying that doctors inevitably occupy a
special position in this issue,2 and not just
Achievement of serum cholesterol value of ≤5 mmol/l and use of maximum dose of individual lipid agents
Agent
Maximum
dosage
No (%) with
cholesterol >5mmol/l
No (%) with
cholesterol ≤5 mmol/l Total
P value (2 or
Fisher’s exact test)
Simvastatin No 362 (40.7) 528 (59.3) 890 0.233
Yes 4 (66.7) 2 (33.3) 6
Total 366 (40.8) 530 (59.2) 896
Pravastatin No 58 (51.8) 54 (48.2) 112 0.18
Yes 16 (66.7) 8 (33.3) 24
Total 74 (54.4) 62 (45.6) 136
Cerivastatin No 63 (41.2) 90 (58.8) 153 0.004
Yes 53 (60.2) 35 (39.8) 88
Total 116 (48.1) 125 (51.9) 241
Fluvastatin No 36 (61.0) 23 (39.0) 59 0.06
Yes 6 (100) 0 6
Total 42 (64.6) 23 (35.4) 65
Atorvastatin No 377 (40.3) 558 (59.7) 935 0.78
Yes 7 (43.8) 9 (56.3) 16
Total 384 (40.4) 567 (59.6) 951
Fibrates and others No 11 (73.3) 4 (26.7) 15 0.92
Yes 123 (74.5) 42 (25.5) 165
Total 134 (74.4) 46 (25.6) 180
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